Mobility – how well we walk – is an important marker of health; a slow walking speed is associated with a greater risk of disease, cognitive decline, risk of falls and even earlier death. As the population ages, the number of people experiencing mobility issues is expected to rise. However, accurately assessing people’s mobility, especially in the real world, is far from easy. MOBILISE-D aims to develop a comprehensive system to analyse people’s gait based on digital technologies, including sensors worn on the body. The project focuses on conditions which often affect mobility, namely chronic obstructive pulmonary disease (COPD), Parkinson’s disease, multiple sclerosis, hip fracture recovery, and congestive heart failure. The project plans to work closely with regulators and other stakeholders to ensure that the solutions are accepted. Once validated, the MOBILISE-D results will help to improve the accurate assessment of mobility in clinical trials. They will also make it easier for clinicians to monitor patients’ mobility and thereby contribute to improved, more personalised care.
MOBILISE-D
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
FACTS & FIGURES
| Start Date |
|
| End Date |
|
| Call |
IMI2 - Call 13
|
| Grant agreement number |
820820
|
Type of Action:
RIA (Research and Innovation Action)
| Contributions | € |
|---|---|
| IMI Funding |
25 395 897
|
| EFPIA in kind |
23 965 667
|
| Total Cost |
49 361 564
|
Summary
Participants Show participants on map
EFPIA companies
- Amgen Limited, Cambridge, United Kingdom
- Astrazeneca AB, Södertälje, Sweden
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Eresearch Technology Inc, Philadelphia, United States
- Grunenthal GMBH, Aachen, Germany
- Icon Clinical Research Limited, Dublin, Ireland
- Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
- Takeda Development Centre Europe LTD., London, United Kingdom
- Teva Pharmaceutical Industries Limited, Netanya, Israel
Universities, research organisations, public bodies, non-profit groups
- Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
- Centre Hospitalier Universitaire Montpellier, Montpellier, France
- Christian-Albrechts-Universitaet Zu Kiel, Kiel, Germany
- Ecole Polytechnique Federale De Lausanne, Lausanne, Switzerland
- Friedrich-Alexander-Universitaet Erlangen Nuernberg, Erlangen, Germany
- Fundacion Privada Instituto De Salud Global Barcelona, Barcelona, Spain
- Imperial College Of Science Technology And Medicine, London, United Kingdom
- Katholieke Universiteit Leuven, Leuven, Belgium
- Norges teknisk-naturvitenskapelige universitet - NTNU, Trondheim, Norway
- Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany
- The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv, Tel Aviv, Israel
- The University Of Sheffield, Sheffield, United Kingdom
- Universita Vita-Salute San Raffaele, Milano, Italy
- Universitat Zurich, Zürich, Switzerland
- Universitatsklinikum Erlangen, Erlangen, Germany
- University College Dublin, National University Of Ireland, Dublin, Dublin, Ireland
- University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
- University Of Northumbria At Newcastle, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Ixscient Limited, Uxbridge, United Kingdom
- Mcroberts BV, S Gravenhage, Netherlands
- Penumologisches Forschungsinstitutan Der Lungenclinic Grosshansdorf GMBH, Grosshansdorf, Germany
- Universita Degli Studi Di Sassari, Sassari, Italy
Third parties
- Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, United Kingdom
- The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom
| Participants | |
|---|---|
| Name | IMI funding in € |
| Alma Mater Studiorum - Universita Di Bologna | 855 665 |
| Centre Hospitalier Universitaire Montpellier | 514 685 |
| Christian-Albrechts-Universitaet Zu Kiel | 973 944 |
| Ecole Polytechnique Federale De Lausanne | 993 625 |
| Friedrich-Alexander-Universitaet Erlangen Nuernberg | 847 864 |
| Fundacion Privada Instituto De Salud Global Barcelona | 1 597 781 |
| Imperial College Of Science Technology And Medicine | 392 415 |
| Ixscient Limited | 464 000 |
| Katholieke Universiteit Leuven | 833 536 |
| Mcroberts BV | 592 188 |
| Norges teknisk-naturvitenskapelige universitet - NTNU | 2 163 524 |
| Penumologisches Forschungsinstitutan Der Lungenclinic Grosshansdorf GMBH | 796 413 |
| Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh | 2 647 171 |
| The Foundation For Medical Research Infrastructural Development And Health Services Next To The Medical Center Tel Aviv | 1 117 625 |
| The University Of Sheffield | 1 334 953 |
| Universita Degli Studi Di Sassari | 391 250 |
| Universita Vita-Salute San Raffaele | 705 980 |
| Universitat Zurich | 511 875 |
| Universitatsklinikum Erlangen | 1 126 930 |
| University College Dublin, National University Of Ireland, Dublin | 1 484 050 |
| University Of Newcastle Upon Tyne | 3 737 460 |
| University Of Northumbria At Newcastle | 434 136 |
| Third parties | |
| Name | IMI funding in € |
| Sheffield Teaching Hospitals Nhs Foundation Trust | 759 888 |
| The Newcastle Upon Tyne Hospitals Nhs Foundation Trust | 118 940 |
| Total Cost | 25 395 898 |
CONTACT
Project coordinator
Lynn ROCHESTER
UNIVERSITY OF NEWCASTLE UPON TYNE
Lynn.Rochester[at]ncl.ac.uk
Lynn ROCHESTER
UNIVERSITY OF NEWCASTLE UPON TYNE
Lynn.Rochester[at]ncl.ac.uk